# BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

> **NCT01248247** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 334 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** AZD6244
- **DRUG:** MK-2206
- **DRUG:** Sorafenib
- **DRUG:** Erlotinib
- **DRUG:** MK-2206

## Key facts

- **NCT ID:** NCT01248247
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-02
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 334 (ACTUAL)
- **Last updated:** 2022-01-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01248247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01248247, "BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01248247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*